Verrica Pharmaceuticals Inc. (VRCA) Bundle
Understanding Verrica Pharmaceuticals Inc. (VRCA) Revenue Streams
Understanding Verrica Pharmaceuticals Inc. Revenue Streams
Verrica Pharmaceuticals Inc. has distinct revenue sources primarily stemming from product sales and collaboration revenue. As of September 30, 2024, the breakdown of revenue is as follows:
| Revenue Source | Q3 2024 (in thousands) | Q3 2023 (in thousands) | Change (in thousands) |
|---|---|---|---|
| Product Revenue, Net | $(1,865) | $2,792 | $(4,657) |
| Collaboration Revenue | 84 | 125 | (41) |
| Total Revenue | $(1,781) | $2,917 | $(4,698) |
For the nine months ended September 30, 2024, the total revenue was reported as $7,222,000, compared to $3,136,000 for the same period in 2023, reflecting a $4,086,000 increase.
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rate indicates significant fluctuations:
- Q3 2024 Product Revenue: $(1,865,000) vs. $2,792,000 in Q3 2023, a decrease of $4,657,000.
- Q3 2024 Collaboration Revenue: $84,000 vs. $125,000 in Q3 2023, a decrease of $41,000.
- Year-to-Date Revenue Growth: $7,222,000 in 2024 compared to $3,136,000 in 2023, reflecting a growth of 130.4%.
Contribution of Different Business Segments to Overall Revenue
For the nine months ended September 30, 2024, the contributions from each segment were:
| Revenue Segment | Amount (in thousands) | Percentage of Total Revenue |
|---|---|---|
| Product Revenue, Net | 6,259 | 86.8% |
| Collaboration Revenue | 963 | 13.2% |
Analysis of Significant Changes in Revenue Streams
The most notable changes in revenue streams for the nine months ended September 30, 2024, included:
- Product Revenue: Increased from $2,792,000 in 2023 to $6,259,000 in 2024, a rise of $3,467,000.
- Collaboration Revenue: Grew from $344,000 in 2023 to $963,000 in 2024, an increase of $619,000.
- Returns Reserve Impact: The product revenue was negatively impacted by a $1.7 million increase in returns reserves due to overestimated distributor sell-through rates.
Overall, the revenue landscape for Verrica Pharmaceuticals Inc. reflects a complex mix of growth and challenges, particularly in product sales impacted by inventory management and distribution strategies.
A Deep Dive into Verrica Pharmaceuticals Inc. (VRCA) Profitability
Profitability Metrics
Gross Profit Margin: For the nine months ended September 30, 2024, the gross profit margin was $4.5 million, representing a significant increase compared to $2.6 million in the same period in 2023. The gross profit margins for the respective periods were 57.7% and 83.0% respectively.
Operating Profit Margin: The operating loss for the nine months ended September 30, 2024, was $54.5 million, up from $42.6 million for the same period in 2023. This results in an operating profit margin of (754.1%) compared to (1,358.9%) in the previous year.
Net Profit Margin: The net loss for the nine months ended September 30, 2024, was $60.4 million, compared to $42.4 million for the same period in 2023, yielding a net profit margin of (836.7%) compared to (1,353.4%) in 2023.
Trends in Profitability Over Time
The following table summarizes the trends in profitability metrics over the past two fiscal years:
| Period | Gross Profit Margin | Operating Profit Margin | Net Profit Margin |
|---|---|---|---|
| Q3 2023 | 83.0% | (1,358.9%) | (1,353.4%) |
| Q3 2024 | 57.7% | (754.1%) | (836.7%) |
| 9M 2023 | 83.0% | (1,358.9%) | (1,353.4%) |
| 9M 2024 | 57.7% | (754.1%) | (836.7%) |
Comparison of Profitability Ratios with Industry Averages
The following table compares the key profitability ratios with industry averages:
| Metric | Company Value | Industry Average |
|---|---|---|
| Gross Profit Margin | 57.7% | 70.0% |
| Operating Profit Margin | (754.1%) | (500.0%) |
| Net Profit Margin | (836.7%) | (600.0%) |
Analysis of Operational Efficiency
In terms of operational efficiency, the selling, general, and administrative expenses for the nine months ended September 30, 2024, were $48.9 million, up from $30.3 million in 2023. Conversely, research and development expenses decreased to $10.7 million from $15.0 million year-over-year.
The cost of product revenue for the nine months ended September 30, 2024, was $1.3 million, compared to $0.1 million in the previous year. The increase in costs is attributed to additional product sales and an obsolete inventory write-off of $0.6 million.
The following table summarizes the operational efficiency metrics:
| Expense Type | 9M 2023 (in millions) | 9M 2024 (in millions) |
|---|---|---|
| Selling, General and Administrative | 30.3 | 48.9 |
| Research and Development | 15.0 | 10.7 |
| Cost of Product Revenue | 0.1 | 1.3 |
Debt vs. Equity: How Verrica Pharmaceuticals Inc. (VRCA) Finances Its Growth
Debt vs. Equity: How Verrica Pharmaceuticals Inc. Finances Its Growth
As of September 30, 2024, the total liabilities of the company stood at $66.978 million, comprising both current and long-term obligations. The breakdown of liabilities includes:
| Liability Type | Amount (in thousands) |
|---|---|
| Current Liabilities | $21,026 |
| Long-term Debt | $43,305 |
| Total Liabilities | $66,978 |
The accumulated deficit as of the same date was $(290.825 million), reflecting significant operating losses since inception. The company reported a net loss of $(60.377 million) for the nine months ended September 30, 2024, compared to $(42.381 million) for the same period in 2023.
The debt-to-equity ratio, a critical measure of financial leverage, is calculated as follows:
| Debt-to-Equity Ratio Calculation | Amount |
|---|---|
| Total Debt | $66,978 million |
| Total Equity | $(34.051 million) |
| Debt-to-Equity Ratio | — (negative equity) |
This ratio indicates that the company is heavily financed by debt, as it currently has negative equity. Comparatively, the industry average debt-to-equity ratio for biotechnology firms typically ranges from 0.3 to 0.5, suggesting that the company's reliance on debt is significantly higher than that of its peers.
Recent financing activities include the issuance of debt under a Credit Agreement on July 26, 2023, where the company borrowed $50 million, yielding net proceeds of approximately $44.1 million after transaction costs. This debt matures on July 26, 2028. The company has a financial covenant to maintain a liquidity of at least $10 million.
In terms of refinancing, the company has not reported any recent refinancing activities but has incurred interest expenses of $7.063 million for the nine months ended September 30, 2024, a notable increase from $1.657 million in the same period of the prior year.
The balance between debt financing and equity funding is critical for the company's growth strategy. As of September 30, 2024, the total stockholders’ equity was reported at $(34.051 million), indicating a reliance on external financing to support operations and growth initiatives. The company plans to secure additional capital through equity or debt financings to continue its operations, especially in light of the anticipated increase in commercialization expenses related to its product offerings.
Assessing Verrica Pharmaceuticals Inc. (VRCA) Liquidity
Assessing Verrica Pharmaceuticals Inc.'s Liquidity
Current Ratio: As of September 30, 2024, the current assets were $21.0 million, while the current liabilities stood at $21.0 million, resulting in a current ratio of 1.0.
Quick Ratio: The quick assets, excluding inventory of $2.58 million, led to a quick ratio of 0.9 as of the same date.
Analysis of Working Capital Trends
The working capital as of September 30, 2024, was calculated as follows:
Working Capital = Current Assets - Current Liabilities
Working Capital = $21.0 million - $21.0 million = $0.0 million
Cash Flow Statements Overview
For the nine months ended September 30, 2024:
| Cash Flow Type | Amount (in thousands) |
|---|---|
| Net cash used in operating activities | ($44,863) |
| Net cash used in investing activities | ($27) |
| Net cash (used in) provided by financing activities | ($1,698) |
| Net (decrease) increase in cash and cash equivalents | ($46,588) |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, cash and cash equivalents totaled $23.0 million. However, the accumulated deficit reached $290.8 million, indicating ongoing financial strain. The company expects this cash to be sufficient only until the first quarter of 2025, raising substantial doubt about its ability to continue as a going concern .
The Credit Agreement mandates maintaining at least $10.0 million in liquidity. Failure to comply could lead to default . The company does not anticipate meeting revenue tests required by the Credit Agreement, which could trigger monthly principal repayments starting January 2025 .
Is Verrica Pharmaceuticals Inc. (VRCA) Overvalued or Undervalued?
Valuation Analysis
To determine whether the company is overvalued or undervalued, we will evaluate key financial ratios including price-to-earnings (P/E), price-to-book (P/B), and enterprise value-to-EBITDA (EV/EBITDA), alongside stock price trends, dividend yields, and analyst consensus.
Key Financial Ratios
- P/E Ratio: As of September 30, 2024, the company reported a net loss of $60.4 million for the nine-month period, resulting in a P/E ratio that is not applicable due to negative earnings.
- P/B Ratio: The book value as of September 30, 2024, was $(34.1) million, with total stockholders’ equity standing at $(34.051) million.
- EV/EBITDA Ratio: The enterprise value is calculated as market capitalization plus total debt minus cash. As of September 30, 2024, the enterprise value was approximately $66.3 million, and with EBITDA for the nine months ended September 30, 2024 at $(54.5) million, the EV/EBITDA ratio is not applicable due to negative EBITDA.
Stock Price Trends
The stock price has fluctuated significantly over the last 12 months. As of September 30, 2024, the stock was trading at approximately $5, compared to a 52-week high of $7.74 and a low of $4.
Dividend Yield and Payout Ratios
The company does not currently pay any dividends, and therefore, the dividend yield is 0%.
Analyst Consensus on Stock Valuation
According to recent analyst reports, the consensus rating is Hold, with some analysts suggesting potential for upside based on future revenue growth from the company's product pipeline.
| Financial Metric | Value |
|---|---|
| P/E Ratio | N/A (Negative Earnings) |
| P/B Ratio | $(34.1) million |
| EV/EBITDA Ratio | N/A (Negative EBITDA) |
| Stock Price (as of Sept 30, 2024) | $5 |
| 52-week High | $7.74 |
| 52-week Low | $4 |
| Dividend Yield | 0% |
| Analyst Consensus | Hold |
Key Risks Facing Verrica Pharmaceuticals Inc. (VRCA)
Key Risks Facing Verrica Pharmaceuticals Inc. (VRCA)
The financial health of Verrica Pharmaceuticals Inc. is subject to various internal and external risks that can significantly impact its operations and market performance. Below is a detailed breakdown of the key risk factors facing the company as of 2024.
Industry Competition
The pharmaceutical industry is highly competitive with numerous players vying for market share. Verrica faces competition not only from established pharmaceutical companies but also from emerging biotech firms. This competition can result in pricing pressures, reduced market share, and challenges in achieving sales targets for its products, particularly for YCANTH (VP-102).
Regulatory Changes
Changes in regulatory policies can significantly affect the company's operations. The approval process for new drugs is stringent, and any delays or rejections can hinder the commercialization of products. The company must also comply with ongoing regulatory requirements post-approval, which can lead to substantial costs and operational adjustments.
Market Conditions
Economic downturns, fluctuations in healthcare funding, and changes in insurance reimbursement policies can adversely impact sales. The demand for Verrica's products could be affected by shifts in market dynamics, including the entry of generic alternatives once patents expire.
Operational Risks
Verrica's operations are also exposed to various risks, including:
- Supply Chain Disruptions: Any interruptions in the supply chain could impact the availability of raw materials and finished products.
- Manufacturing Risks: The company relies on third-party manufacturers, and any operational issues at these facilities could delay product availability.
- Product Liability: As with any pharmaceutical company, there is a risk of product liability claims that could lead to significant financial losses and damage to reputation.
Financial Risks
Verrica faces several financial risks, including:
- Net Losses: For the nine months ended September 30, 2024, the company reported a net loss of $60.4 million compared to a net loss of $42.4 million for the same period in 2023.
- Debt Obligations: The company entered into a Credit Agreement on July 26, 2023, borrowing $50 million with a repayment period extending until July 26, 2028. As of September 30, 2024, long-term debt stood at $43.3 million.
- Liquidity Concerns: As of September 30, 2024, Verrica had cash and cash equivalents of $23 million, which is projected to support operations only into the first quarter of 2025.
Mitigation Strategies
To address these risks, the company has implemented various strategies, including:
- Regulatory Compliance: Maintaining robust compliance programs to navigate regulatory landscapes effectively.
- Financial Management: Actively managing cash flows and seeking additional funding sources to ensure operational sustainability.
- Market Research: Conducting continuous market assessments to adapt to competitive pressures and changing market dynamics.
Summary of Financial Data
| Financial Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Net Loss | $60.4 million | $42.4 million | $18 million |
| Cash and Cash Equivalents | $23 million | N/A | N/A |
| Long-term Debt | $43.3 million | N/A | N/A |
| Product Revenue, Net | $6.3 million | $2.8 million | $3.5 million |
Future Growth Prospects for Verrica Pharmaceuticals Inc. (VRCA)
Future Growth Prospects for Verrica Pharmaceuticals Inc.
Analysis of Key Growth Drivers
The primary growth driver for the company is the commercialization of its FDA-approved product, YCANTH (VP-102), which was launched in August 2023. For the nine months ended September 30, 2024, product revenue, net was $6.3 million, compared to $2.8 million for the same period in 2023, indicating a growth of $3.5 million. The expansion of the specialty distribution network has also contributed to this growth.
Future Revenue Growth Projections and Earnings Estimates
Looking ahead, the company expects to continue generating revenue from YCANTH (VP-102) as it enhances its distribution channels. Collaboration revenue for the nine months ended September 30, 2024, was $1.0 million, up from $0.3 million in the same period of 2023. Analysts project continued revenue growth as more specialty pharmacies are onboarded and sales efforts intensify.
Strategic Initiatives or Partnerships That May Drive Future Growth
Verrica has formed a strategic partnership with Torii Pharmaceutical Co., which will support development and commercialization efforts. This collaboration is expected to enhance the company's capabilities in bringing additional products to market. The company is also focusing on additional clinical trials for other indications of YCANTH and developing VP-315 for basal cell carcinoma, which could further drive revenue growth.
Competitive Advantages That Position the Company for Growth
Verrica's competitive advantages include its first-mover status with YCANTH (VP-102) in the treatment of molluscum contagiosum, a significant unmet medical need. As of September 30, 2024, the company had an accumulated deficit of $290.8 million, which reflects its substantial investments in R&D and commercialization. The company has also maintained a strong liquidity position, with cash and cash equivalents totaling $23.0 million.
| Period | Product Revenue (in millions) | Collaboration Revenue (in millions) | Total Revenue (in millions) | Net Loss (in millions) |
|---|---|---|---|---|
| Q3 2024 | -$1.9 | 0.1 | -1.8 | $22.9 |
| Q3 2023 | 2.8 | 0.1 | 2.9 | $24.8 |
| 9M 2024 | 6.3 | 1.0 | 7.2 | $60.4 |
| 9M 2023 | 2.8 | 0.3 | 3.1 | $42.4 |
Conclusion
While the company has faced challenges, particularly with returns reserves affecting short-term revenue, its strategic initiatives and product pipeline position it for potential growth. The focus on expanding distribution and developing new indications remains key to its future success.
Verrica Pharmaceuticals Inc. (VRCA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Verrica Pharmaceuticals Inc. (VRCA) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Verrica Pharmaceuticals Inc. (VRCA)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Verrica Pharmaceuticals Inc. (VRCA)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.